 Connection
Marc Bonaca to Fibrinolytic Agents
This is a "connection" page, showing publications Marc Bonaca has written about Fibrinolytic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.793 |
|
|
|
-
Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
Score: 0.605
-
Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2?P-TIMI 50 trial. Vasc Med. 2020 04; 25(2):124-132.
Score: 0.577
-
Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Curr Cardiol Rep. 2020 Jan 29; 22(3):13.
Score: 0.577
-
Bonaca MP. Polyvascular disease and risk: When two is not better than one. Vasc Med. 2018 12; 23(6):531-533.
Score: 0.525
-
Bonaca MP. Antithrombotic Therapy in Patients With Peripheral Artery Disease. JAMA Cardiol. 2016 10 01; 1(7):803-804.
Score: 0.458
-
Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, Barnathan ES, Bonaca MP. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thromb Haemost. 2024 Jul; 124(7):649-655.
Score: 0.188
-
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 05 05; 29(5):e181-e189.
Score: 0.169
-
Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021 06 11; 128(12):1868-1884.
Score: 0.159
-
De Luca L, Bonaca MP, Magnani G. Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Rev Cardiovasc Ther. 2020 Dec; 18(12):881-889.
Score: 0.152
-
Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferri?res J, Schiele F, Simon T, Danchin N, Puymirat E. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. Eur J Prev Cardiol. 2019 03; 26(4):411-419.
Score: 0.132
-
Bonaca MP, Creager MA. Antithrombotic Therapy and Major?Adverse Limb Events in Peripheral?Artery?Disease: A Step Forward. J Am Coll Cardiol. 2018 05 22; 71(20):2316-2318.
Score: 0.128
-
Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014 Apr; 167(4):437-444.e5.
Score: 0.095
-
Berg DD, Bonaca MP, Braunwald E, Corbalan R, Goto S, Kiss RG, Murphy SA, Scirica BM, Spinar J, Morrow DA. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2?P-TIMI 50). Am J Cardiol. 2016 Apr 01; 117(7):1055-8.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|